News George gets FDA nod for first blood pressure triple therapy George Medicines' Widaplik can address key challenges in current hypertension treatment, according to the UK drugmaker's CEO.
News ACC25: Mineralys' uncontrolled hypertension drug aces trial Mineralys looks odds on to become the first drug developer to bring an aldosterone synthase inhibitor to market for uncontrolled hypertension.
News When licensing deals go bad - Novo sues KBP Bio for $830m Novo Nordisk lawsuit claims KBP concealed clinical data ahead of a $1.3bn licensing deal for blood pressure drug candidate ocedurenone.
News Study backs Closed Loop's drug+digital blood pressure plan Closed Loop Medicine's smartphone app for blood pressure monitoring has shown proof-of-concept in the Cure-19 study.
News Novo sheds kidney drug licensed for $1.3bn a year ago Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.
R&D A spectrum of obesity requires precision Obesity is a hot topic, and a focal research area, in the twentieth century.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
